Antipneumococcal activity of LBM415, a new peptide biformylase inhibitor, compared with those of other agents

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 10, 2004, Pages 4027-4032

  Ednie, Lois M ^a   Pankuch, Glenn ^a   Appelbaum, Peter C ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; AZITHROMYCIN; BETA LACTAM; CEFDINIR; CEFPODOXIME; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; CLARITHROMYCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; GATIFLOXACIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MACROLIDE; MEROPENEM; MOXIFLOXACIN; N (5 FLUORO 1 OXIDO 2 PYRIDINYL) 1 [2 (N FORMYL N HYDROXYAMINOMETHYL)HEXANOYL]PROLINAMIDE; PENICILLIN G; PEPTIDE DEFORMYLASE INHIBITOR; QUINOLONE; TEICOPLANIN; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIA;

AMIDOHYDROLASES; ANTI-BACTERIAL AGENTS; COLONY COUNT, MICROBIAL; ENZYME INHIBITORS; KINETICS; MICROBIAL SENSITIVITY TESTS; PEPTIDES; STREPTOCOCCUS PNEUMONIAE;

EID: 4644249672     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.10.4027-4032.2004     Document Type: Article

References (25)

1. Anderegg, T. R., D. J. Biedenbach, R. N. Jones, and the Quality Control Working Group. 2003. Quality control guidelines for MIC susceptibility testing of NVP-PDF713, a novel peptide deformylase inhibitor. Int. J. Antimicrob. Agents 22:84-86.
2. Anderegg, T. R., R. N. Jones, and the Quality Control Working Group. 2004. Disk diffusion quality control guidelines for NVP-PDF 713: a novel peptide deformylase inhibitor. Diagn. Microbiol. Infect. Dis. 48:55-57.
3. Appelbaum, P. C. 1992. Antimicrobial resistance in Streptococcus pneumonias - an overview. Clin. Infect. Dis. 15:77-83.
4. Cercenado, E., F. Garcia-Garrote, and E. Bouza. 2001. In-vitro activity of linezolid against multiply resistant gram-positive clinical isolates. J. Antimicrob. Chemother. 47:77-81.
5. Diekema, D. J., and R. N. Jones. 2000. Oxazolidinones. A review. Drugs 59:7-16.
6. Friedland, I. R., and G. H. McCracken, Jr. 1994. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N. Engl. J. Med. 331:377-382.
7. Pritsche, T. R., G. J. Meet, and R. N. Jones. Commercial broth microdilution panel validation and reproducibility trials for NVP-PDF 713, a novel inhibitor of bacterial peptide deformylase. Clin. Microbiol. Infect., in press.
8. Henwood, C. J., D. M. Livermore, A. P. Johnson, D. James, M. Warner, A. Gardiner, and the Linezolid Study Group. 2000. Susceptibility of gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. J. Antimicrob. Chemother. 46:931-940.
9. Hoellman, D. B., G. Lin, L. M. Ednie, A. Rattan, M. R. Jacobs, and P. C. Appelbaum. 2003. Antipneumococcal and antistaphylococcal activities of ranbezolid (RBX 7644), a new oxazolidinone, compared to those of other agents. Antimicrob. Agents Chemother. 47:1148-1150.
10. Jacobs, M. R., and P. C. Appelbaum. 1995. Antibiotic-resistant pneumococci. Rev. Med. Microbiol. 6:77-93.
11. Jacobs, M. R., S. Bajaksouzian, A. Zilles, G. Lin, G. A. Pankuch, and P. C. Appelbaum. 1999. Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. surveillance study. Antimicrob. Agents Chemother. 43:1901-1908.
12. Jones, R. N., T. R. Pritsche, and H. S. Sader. 2004. Antimicrobial spectrum and activity of NVP-PDF 713, a novel peptide deformylase inhibitor, tested against 1,837 recent gram-positive clinical isolates. Diagn. Microbiol. Infect. Dis. 49:63-65.
13. Jones, R. N., G. J. Meet, H. S. Sader, and T. R. Pritsche. 2004. Potential utility of a peptide deformylase inhibitor (NVP-PDF 713) against oxazolidinone-resistant or streptogramin-resistant gram-positive organism isolates. J. Antimicrob. Chemother. 53:804-807.
14. Jones, R. N., and P. R. Rhomberg. 2003. Comparative spectrum and activity of NVP-PDF386 (VRC4887), a new peptide deformylase inhibitor. J. Antimicrob. Chemother. 51:157-161.
15. Linares, J., A. G. Campa, and R. Pallares. 1999. Fluoroquinolone- resistance in Streptococcus pneumoniae. N. Engl. J. Med. 20:1546-1548.
16. Livermore, D. M. 2000. Quinupristin/dalfopristin and linezolid: where, when, which and whether to use? J. Antimicrob. Chemother. 46:347-350.
17. National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 6th ed.; approved standard. NCCLS publication no. M7-A6. National Committee for Clinical Laboratory Standards, Wayne, Pa.
18. Pankuch, G. A., M. R. Jacobs, and P. C. Appelbaum. 1994. Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology. Antimicrob. Agents Chemother. 38:2065-2072.
19. Pankuch, G. A., M. R. Jacobs, and P. C. Appelbaum. 1995. Comparative activity of ampicillin, amoxycillin, amoxycillin/clavulanate and cefotaxime against 189 penicillin-susceptible and -resistant pneumococci. J. Antimicrob. Chemother. 35:883-888.
20. Pankuch, G. A., M. R. Jacobs, and P. C. Appelbaum. 2003. Bactericidal activity of daptomycin against Streptococcus pneumoniae compared with eight other antimicrobials. J. Antimicrob. Chemother. 51:443-446.
21. Spangler, S. K., M. R. Jacobs, and P. C. Appelbaum. 1992. Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD131628, sparfloxacin, temafloxacin, Win 57273, ofloxacin, and ciprofloxacin. Antimicrob. Agents Chemother. 36:856-859.
22. Spangler, S. K., M. R. Jacobs, G. A. Pankuch, and P. C. Appelbaum. 1993. Susceptibility of 170 penicillin-susceptible and -resistant pneumococci to six oral cephalosporins, four quinolones, desacetylcefotaxime, Ro 23-9424 and RP 67829. J. Antimicrob. Chemother. 31:273-280.
23. Stevens, D. L., L. G. Smith, J. B. Brass, M. A. McConnell-Martin, S. E. Duvall, W. M. Todd, and B. Hafkin. 2000. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob. Agents Chemother. 44:3408-3413.
24. Visalli, M. A., M. R. Jacobs, and P. C. Appelbaum. 1996. MIC and time-kill study of DU-6859a, ciprofloxacin, levofloxacin, sparfloxacin, cefotaxime, imipenem, and vancomycin against nine penicillin-susceptible and -resistant pneumococci. Antimicrob. Agents Chemother. 40:362-366.
25. Visalli, M. A., M. R. Jacobs, and P. C. Appelbaum. 1997. Antipneumococcal activity of BAY 12-8039, a new quinolone, compared with activities of three other quinolones and four β-lactams. Antimicrob. Agents Chemother. 41: 2786-2789.